News

Abbott (ABT) reported $10.97 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 7.2%. EPS of $1.34 for the same period compares to $1.19 a year ago.

The reported revenue represents a surprise of -0.45% over the Zacks Consensus Estimate of $11.02 billion. With the consensus EPS estimate being $1.34, the company has not delivered EPS surprise.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Abbott performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net sales- Diagnostics- U.S. $1.06 billion compared to the $1.03 billion average estimate based on five analysts. The reported number represents a change of +3.4% year over year.
• Net sales- Diagnostics- International: $1.47 billion versus the five-analyst average estimate of $1.54 billion. The reported number represents a year-over-year change of -3.2%.
• Net sales- Nutrition- International: $1.20 billion compared to the $1.21 billion average estimate based on five analysts. The reported number represents a change of +2% year over year.
• Net sales- Nutrition- U.S. $928 million versus the five-analyst average estimate of $942.92 million. The reported number represents a year-over-year change of +7.9%.
• Net sales- Medical Devices- Rhythm Management- Total: $624 million versus the five-analyst average estimate of $623.50 million. The reported number represents a year-over-year change of +7.2%.
• Net sales- Medical Devices- Diabetes Care: $1.86 billion compared to the $1.82 billion average estimate based on five analysts. The reported number represents a change of +20% year over year.
• Net sales- Established Pharmaceuticals: $1.27 billion compared to the $1.31 billion average estimate based on five analysts. The reported number represents a change of +3.8% year over year.
• Net sales- Diagnostics: $2.52 billion compared to the $2.57 billion average estimate based on five analysts. The reported number represents a change of -0.6% year over year.
• Net sales- Nutrition: $2.13 billion compared to the $2.16 billion average estimate based on five analysts. The reported number represents a change of +4.5% year over year.
• Net sales- Medical Devices- Vascular- Total: $725 million versus $714.22 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +7.1% change.
• Net sales- Medical Devices- Neuromodulation- Total: $257 million compared to the $253.01 million average estimate based on five analysts. The reported number represents a change of +7.1% year over year.
• Net sales- Medical Devices- Structural Heart- Total: $609 million compared to the $587.72 million average estimate based on five analysts. The reported number represents a change of +22.3% year over year.

View all Key Company Metrics for Abbott here>>>

Shares of Abbott have returned +1.8% over the past month versus the Zacks S&P 500 composite's +2.1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Abbott Laboratories (ABT) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.